Ardelyx, Inc. Stock News

Ardelyx's Q3 revenue grew to $98 million, with strong Xphozah sales despite CMS's recent bundling ruling impacting future reimbursement. The CMS lawsuit dismissal affected Xphozah's reimbursement prospects, creating significant regulatory uncertainty and limiting Ardelyx's revenue control. Ibsrela faces substantial competition in the IBS-C market, with lofty revenue projections likely overstati...

Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients' health at risk Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients' health at risk

WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, Justin Renz, Chief Financial and Operations Officer and Eric Foster, Chief Commercial Officer...

Ardelyx, Inc. (NASDAQ:ARDX ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Michael Raab - President & Chief Executive Officer Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial Officer & Chief Operations Officer Conference Call Participants Louise Chen - Cantor F...

IBSRELA generates $40.6 million in net product sales revenue; Company expects full year 2024 IBSRELA net sales revenue to be between $145 and $150 million

Ninety percent of survey participants reported “some” or “significant” negative impact of IBS-C on their life Survey results presented in two poster presentations WALTHAM, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet...

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of long-term stockholders following a class action complaint that was filed against Ardelyx on August 16, 2024, with a Class Period from October 31, 2023 to July 1, 2024. Our investigation c...

WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the launch of Gut Matters: Discoveries and Innovations, a new podcast for the irritable bowel syndrome with constipation (IBS-C) pa...